Meta-Analysis the Effectiveness of Ivermectin Use on the Length of Stay in Inpatients of COVID-19
Abstract
Background: COVID-19 is a common problem in global health. COVID-19 is a disease that infects the respiratory tract caused by the Coronavirus virus. Symptoms range from mild to severe and life-threatening pneumonia can occur. At the beginning of the PSBB, information circulated that Ivemectin could treat COVID-19 infections. Ivermectin is an antiparasitic drug that can be used as prophylaxis and therapy for coronavirus disease 2019. Ivermectin is an alternative therapy for COVID-19 because there is a previous drug, chloroquine, which can be used to treat COVID-19. This study aims to estimate the effectiveness of Ivermectin on the duration of hospitalization of patients with COVID-19 based on the results of previous similar studies.
Subjects and Method: This study is a meta-analysis with the following PICO, population: COVID-19 patients. Intervention: ivermectin. Comparison: standard therapy. Outcome: shorter duration of hospital stay. Meta-analyses and systematic studies using the PubMed, Scopus, Scholar, Springlink, Cochrane, Clinical Key, and Science Direct databases. Keywords using Ivermectin AND RCT AND COVID-19 AND “Coronavirus Disease” AND “NCOV disease” AND “COVID-19 treatment”. The article under study is a full-text article with a randomized controlled clinical trial (RCT) study design. Articles were collected using PRISMA diagrams and analyzed using Review Manager 5.3.
Results A total of 9 Randomized Control Trial (RCT) studies from Europe, America, Asia and Africa were selected for systematic review and meta-analysis. COVID-19 patients receiving Ivermectin therapy decreased the duration of hospital stay by 1.52 units compared to standard therapy and this result was statistically significant (SMD= -1.52; 95% CI= -2.34 to -0.70; p= 0.003).
Conclusion: Ivermectin can reduce the duration of hospital stay for COVID-19 patients.
Keywords: COVID-19, ivermectin, duration hospital stay
Correspondence: Masromi Hendria Wijayanto. Masters Program in Public Health, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta 57126, Jawa Tengah. Email: masromihendria@gmail.com. Mobile: 0895402471549.
Indonesian Journal of Medicine (2022), 07(02): 200-208
https://doi.org/10.26911/theijmed.2022.07.02.08
References
Abd‐Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES, Soliman S, Abd El Gafar MS, et al. (2021). Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study. J Med Virol. 93: 5833‐5838. doi: 10.1002/jmv.27122.
Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. (2021). A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 103:214–6.33.
Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. (2021). Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomised controlled double blind dose response study in Lagos. medRxiv. 2001. 2005.21249131.
Beltran-Gonzalez JL, Gamez MG, Enciso EAM, Maldonado RJE, Palacios DH, Campos SD, Robles IO, et al. (2021). Efficacy and safety of ivermectin and hydroxychloroquine in patients with se-vere COVID-19. A randomized controlled trial. medRxiv [Preprint: not peer reviewed]. February 23, 2021. From: https://www.medrxiv.org/content/10.1101/2021.02.18.21252037v1.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020). The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Antiviral Res. from https://www.ncbi.-nlm.nih.gov/pubmed/32251768
Gorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM, Aljabory AM, Abbas AM, et al. (2021). Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial). medRxiv preprint. doi: 10.1101/2020.07.07.20145979.
Heidary F, Gharebaghi R (2020). Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. Journal of Antibiotics, 73(9), 593–602.
Kant S, Rastogi H, Bajpai J, Aggarwal K (2020). Ivermectin–A Potent Weapon in the Anti-COVID-19 Armamentarium. IJCP. 31(5).
Lim SCL, Hor CP, Tay KH, Jelani AM, Tan WH, Ker HB, Chow TS, et al. (2021). Efficacy of ivermectin treatment on disease progression with mild to moderate COVID-19 and comorbidities the i-tech randomized clinical trial. JAMA Intern Med. 182(4): 426-435. doi: 10.1001/jamainternmed.2022.0189.
Niaee MS, Gheibi N, Namdar P, Allami A, Zolghadr L, Javadi A, Karampour A (2020). Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial.
Podder CS, Chowdhury N, Sina MI, Haque W (2020). Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. IMC J. Med. Sci 14.
Rothan HA Byrareddy SN (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. Elsevier, 109 (February), p. 102433. doi: 10.1016/j.jaut.2020.102433.
Shahbaznejad L, Davoudi A, Eslami G, Markowitz JS, Navaeifar MR, Hosseinzadeh F, Movahedi FS, et al. (2021). Effects of ivermectin in patients with COVID- 19: A multicenter, double-blind, randomized, controlled clinical trial. Clin Ther 2021. 43(6): 1007-1019.
Weiss SR, Navas-martin S (2005). Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus. 69(4): 635–664. doi: 10.1128/MMBR.69.4.635.
Wijaya H, Saraswati NAS, Amanda DA (2021). Ivermectin dan COVID-19: sebuah tinjauan literatur | majalah kesehatan indonesia. (pp. 19-5). https://-ukinstitute.org/journals/1/index.php/makein/article/view/21-9.
Yuliana (2020). Corona virus diseases (COVID-19); Sebuah tinjauan literatur. Wellness and Healthy Magazine (pp. 187–192). Diakses pada 25 Juli 2021, Retrieved from: https://wellness.journ-alpress.id/wellness/article/view/21026.
